Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Analgesic-related chronic kidney disease

INTRODUCTION

Nonnarcotic analgesic agents have been associated with progressive chronic kidney disease (CKD) since the early 1950s [1,2].

Analgesic nephropathy, as it was initially described, is a well-described CKD characterized by renal papillary necrosis and chronic interstitial nephritis, and caused by prolonged and excessive consumption of analgesic mixtures containing aspirin or antipyrine, in combination with phenacetin, paracetamol, or salicylamide and caffeine and/or codeine in proprietary mixtures [3-7]. This entity had well-defined histologic and radiographic features and used to be an important cause of CKD, particularly in Australia, parts of Europe, and the United States [3-5].

However, there was a marked decline in incidence subsequent to the withdrawal of phenacetin from the market and to legislation that made combined analgesics available only by prescription. Since these measures were virtually coincident, it is difficult to determine which measure caused the reduction in incidence.

Subsequent to the decline in incidence of analgesic nephropathy associated with phenacetin-containing and non-phenacetin-containing mixtures, many reports suggested that individual analgesic agents also cause CKD, although the underlying histology and radiographic features are not as well-defined as for analgesic nephropathy associated with phenacetin-containing and non-phenacetin-containing mixtures. CKD due to single analgesic agents is thus less well documented.

This topic reviews the epidemiology of, risk factors for, and pathogenesis of analgesic nephropathy associated with phenacetin-containing and non-phenacetin-containing mixtures, as well as CKD associated with single analgesic agents. The clinical manifestations and diagnosis of analgesic nephropathy and acute kidney injury (AKI) associated with nonsteroidal antiinflammatory agents (NSAIDs) are presented separately. (See "Clinical manifestations and diagnosis of analgesic nephropathy" and "NSAIDs: Acute kidney injury (acute renal failure)".)

            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jan 23, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. SPUHLER O, ZOLLINGER HU. [Chronic interstitial nephritis]. Z Klin Med 1953; 151:1.
  2. Dubach UC, Rosner B, Stürmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324:155.
  3. Buckalew VM Jr, Schey HM. Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine (Baltimore) 1986; 65:291.
  4. De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol 2009; 20:2098.
  5. Pintér I, Mátyus J, Czégány Z, et al. Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant 2004; 19:840.
  6. Noels LM, Elseviers MM, de Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995; 10:167.
  7. Nanra RS. Analgesic nephropathy in the 1990s--an Australian perspective. Kidney Int Suppl 1993; 42:S86.
  8. Nanra RS, Stuart-Taylor J, de Leon AH, White KH. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978; 13:79.
  9. Mihatsch MJ, Hofer HO, Gudat F, et al. Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983; 20:285.
  10. Bach PH, Hardy TL. Relevance of animal models to analgesic-associated renal papillary necrosis in humans. Kidney Int 1985; 28:605.
  11. Duggin GG. Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 1996; 28:S39.
  12. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 1983; 308:357.
  13. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989; 320:1238.
  14. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48:1912.
  15. Dubach UC, Rosner B, Stürmer T. Epidemiologic study of analgesic abuse: mortality study in 7275 working women (1968-1987). Kidney Int 1991; 40:728.
  16. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331:1675.
  17. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant 1994; 9:1371.
  18. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy--an autopsy study. Nephrol Dial Transplant 2006; 21:3139.
  19. Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. Kidney Int 2007; 72:517.
  20. Feinstein AR, Heinemann LA, Curhan GC, et al. Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int 2000; 58:2259.
  21. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998; 338:446.
  22. Michielsen P, de Schepper P. Trends of analgesic nephropathy in two high-endemic regions with different legislation. J Am Soc Nephrol 2001; 12:550.
  23. McLaughlin JK, Lipworth L, Chow WH, Blot WJ. Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int 1998; 54:679.
  24. Delzell E, Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine (Baltimore) 1998; 77:102.
  25. Gault MH, Barrett BJ. Analgesic nephropathy. Am J Kidney Dis 1998; 32:351.
  26. Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. J Nephrol 1998; 11:70.
  27. van der Woude FJ, Heinemann LA, Graf H, et al. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 2007; 8:15.
  28. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801.
  29. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164:1519.
  30. Rexrode KM, Buring JE, Glynn RJ, et al. Analgesic use and renal function in men. JAMA 2001; 286:315.
  31. Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42:234.
  32. Prescott LF. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 1982; 23:75.
  33. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996; 28:S14.
  34. Segasothy M, Suleiman AB, Puvaneswary M, Rohana A. Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 1988; 50:50.
  35. Agodoa LY, Francis ME, Eggers PW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51:573.
  36. Emkey RD, Mills JA. Aspirin and analgesic nephropathy. JAMA 1982; 247:55.
  37. D'Agati V. Does aspirin cause acute or chronic renal failure in experimental animals and in humans? Am J Kidney Dis 1996; 28:S24.
  38. Ibáñez L, Morlans M, Vidal X, et al. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int 2005; 67:2393.
  39. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28:S56.
  40. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115:165.
  41. Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease--still unsettled. Ann Intern Med 1991; 115:227.
  42. Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24:17.
  43. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007; 120:280.e1.
  44. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011; 6:2567.
  45. Wei L, MacDonald TM, Jennings C, et al. Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function. Kidney Int 2013; 84:174.